NASDAQ · BGMS
Healthcare · Medical - Pharmaceuticals
$0.82
Up+$0.02 (+2.31%)
Updated Oct 9, 2026, 3:36 PM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BGMS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
BGMS closed at $0.82 after 21 trading sessions, down 2.85% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $0.8408 | $0.8928 | $0.81 | $0.821 | 16.98K |
| Oct 7, 2026 | $0.8557 | $0.8719 | $0.849 | $0.85 | 5.91K |
| Oct 6, 2026 | $0.8701 | $0.8909 | $0.841 | $0.8557 | 19.77K |
| Oct 5, 2026 | $0.895 | $0.9112 | $0.8684 | $0.8684 | 5.88K |
| Oct 2, 2026 | $0.8801 | $0.9065 | $0.875 | $0.88 | 9.81K |
| Oct 1, 2026 | $0.8701 | $0.9043 | $0.8701 | $0.9043 | 2.22K |
| Sep 30, 2026 | $0.8855 | $0.9257 | $0.8683 | $0.8821 | 8.93K |
| Sep 29, 2026 | $0.88 | $0.9269 | $0.8554 | $0.88 | 9.92K |
| Sep 28, 2026 | $0.95 | $0.95 | $0.8817 | $0.9035 | 7.03K |
| Sep 25, 2026 | $0.9738 | $0.9738 | $0.92 | $0.92 | 16.58K |
| Sep 24, 2026 | $0.9306 | $0.9888 | $0.9306 | $0.945 | 4.67K |
| Sep 23, 2026 | $0.92 | $0.9916 | $0.92 | $0.9622 | 8.83K |
| Sep 22, 2026 | $0.9966 | $0.9983 | $0.9204 | $0.9277 | 17.16K |
| Sep 21, 2026 | $0.93 | $0.9746 | $0.91 | $0.9483 | 23.67K |
| Sep 18, 2026 | $0.909 | $0.9668 | $0.8924 | $0.937 | 70.89K |
| Sep 17, 2026 | $0.9902 | $1.0482 | $0.8782 | $0.8782 | 22.77K |
| Sep 16, 2026 | $1.05 | $1.06 | $0.9202 | $0.9902 | 38.77K |
| Sep 15, 2026 | $0.8356 | $1.18 | $0.82 | $1.0529 | 532.2K |
| Sep 14, 2026 | $0.8509 | $1.16 | $0.6967 | $0.8976 | 2.68M |
| Sep 11, 2026 | $0.852 | $0.873 | $0.8451 | $0.872 | 17.5K |
| Sep 10, 2026 | $0.8704 | $0.8704 | $0.8451 | $0.8451 | 4.97K |
The latest Smart Investors Daily articles mentioning BGMS.
Company
Market Activity
Research & News
BGMS research
Company profile and research snapshot.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Sep 14, 2026
Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million. Eocene (NASDAQ:EOCN) shares rose 10.65% to
Yahoo · Sep 10, 2026
~ Transaction values Firstborn Top Capital at pro forma enterprise value of approximately $1,091.2 million ~~ Firstborn Top Capital is a licensed private financing company committed to providing responsible, transparent and accessible financial solutions to individuals and businesses across Malaysia ~~ Executive Director, Ow Ruey Shen, will continue to lead Firstborn Top Capital ~~ Transaction provides Firstborn Top Capital the capital to accelerate growth throughout Malaysia, then Southeast Asi
Benzinga · Aug 12, 2026
Bio Green Med Solution (NASDAQ:BGMS) reported quarterly losses of $(0.08) per share. This is a 91.4 percent increase over losses of $(0.93) per share from the same period last year. The company reported $336.000
Benzinga · Jul 27, 2026
Gainers Matinas BioPharma Hldgs (AMEX:MTNB) shares increased by 59.7% to $0.39 during Monday's pre-market session. The company's market cap stands at $1.5 million. Forte Biosciences (NASDAQ:FBRX) stock rose
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BGMS.
No results
No recent SID articles mention BGMS.
